<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mucha, Simon R.</style></author><author><style face="normal" font="default" size="100%">Dugar, Siddharth</style></author><author><style face="normal" font="default" size="100%">McCrae, Keith</style></author><author><style face="normal" font="default" size="100%">Joseph, Douglas</style></author><author><style face="normal" font="default" size="100%">Bartholomew, John</style></author><author><style face="normal" font="default" size="100%">Sacha, Gretchen L.</style></author><author><style face="normal" font="default" size="100%">Militello, Michael</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Coagulopathy in COVID-19: Manifestations and management</style></title><secondary-title><style face="normal" font="default" size="100%">Cleveland Clinic Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">461-468</style></pages><doi><style  face="normal" font="default" size="100%">10.3949/ccjm.87a.ccc024</style></doi><volume><style face="normal" font="default" size="100%">87</style></volume><issue><style face="normal" font="default" size="100%">8</style></issue><abstract><style  face="normal" font="default" size="100%">Severe COVID-19 illness is associated with intense inflammation, leading to high rates of thrombotic complications that increase morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings of severe COVID-19– associated coagulopathy. Prophylaxis against venous thromboembolism is paramount for all hospitalized patients, with more aggressive prophylaxis and screening recommended for patients with D-dimer levels above 3.0 μg/mL. Point-of-care ultrasonography is the imaging method of choice for patients at high risk, as it entails minimal risk of exposing providers to the virus.</style></abstract></record></records></xml>